GLS and hematologic disorder: Our novel finding that targeting glutamine metabolism can reduce or reverse platinum resistance has a high potential for clinical translation, since oral glutaminase inhibitors such as CB-839 are currently being evaluated in Phase 1 clinical trials in patients with advanced solid tumors (NCT02071862; ClinicalTrails.gov) and hematological malignancies (NCT02071888; ClinicalTrails.gov).